Skip to content

Psychedelic-assisted therapy: all studies

Page 161 of 294: studies 1,601 to 1,610 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review

Journal of Bioethical Inquiry August 7, 2025 N Brittain, Nicholas Higgins, Mary Barber et al. 4 citations

The rapid growth in psychedelic research raises novel ethical challenges for both research and psychedelic-assisted therapy. Despite these challenges, there is no consensus among researchers, clinicians, patients, and regulators on how these ethical issues may be avoided or managed. This study aimed to identify key ethical issues in psychedelic research and practice in the literature. A scoping...

DOI: 10.1007/s11673-025-10454-3 (opens in new tab) Full text (opens in new tab) Medical law Engineering ethics Research ethics Psychotherapist

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?

Exploration of Neuroscience August 7, 2025 Trevor R. Norman 2 citations

Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches. Psychedelic medications used in conjunction with intensive psychotherapy, so-called psychedelic-assisted psychotherapy (PAP), have been evaluated in a limited...

Response to emotional stimuli weaker in SSRI users compared with psilocybin

The Brown University Psychopharmacology Update August 4, 2025

Use of selective serotonin reuptake inhibitor (SSRI) antidepressants has been associated with reduced intensity of emotional experience. Conversely, some research has shown that use of psilocybin in patients with depression leads to an increase in responsiveness to emotional face stimuli, suggesting that the psychedelic generates a transient elevation in mood. Investigators conducted a...

DOI: 10.1002/pu.31349 (opens in new tab) Psilocybin Cognitive psychology Audiology Hallucinogen

Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.

Front Dement August 4, 2025 Xenia Androni, Rachel J. Boyd, Paul B. Rosenberg et al. 4 citations

Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review,...

DOI: 10.3389/frdem.2025.1605051 (opens in new tab) Full text (opens in new tab) Psychedelics psychedelic compounds Psychedelic exposure New therapies Alzheimer's +3

Ontic Structural Realism, Buddhist Metaphysics, and the Self in Psychedelic Psychotherapy

Philosophy, Psychiatry, & Psychology August 1, 2025 Daniel Stearman

This paper examines recent empirical research on the psychedelic experience and makes sense of the current literature in terms of ontic structural realism, a position in the metaphysics of science which holds that relations are fundamental. This interpretation is maintained by first providing a philosophical framework for the varieties of self-transcendent experiences by implementing a notion...

Pilot Data on Salivary Oxytocin as a Biomarker of LSD Response in Patients with Major Depressive Disorder

Psychoactives August 1, 2025 L. Cazorla, Sylvie Alaux, Caroline Amberger et al.

Despite growing evidence supporting the efficacy of LSD-assisted psychotherapy in treating major depressive disorder (MDD), identifying reliable psychopharmacological biomarkers remains necessary. Oxytocin, a neuropeptide implicated in social bonding and flexibility, is a promising candidate due to its release following serotonergic psychedelic administration in healthy individuals; however,...

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review.

Cureus August 1, 2025 Brett Hughes, Soz Mirza, Manasi Ponamala et al.

The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...

155. EXPLORING LSD MICRODOSING IN AN OPEN-LABEL PILOT FOR MAJOR DEPRESSIVE DISORDER: THE INTERPLAY OF BEHAVIORAL ACTIVATION, MOOD IMPROVEMENT, AND CONNECTEDNESS

The International Journal of Neuropsychopharmacology August 1, 2025 C Donegan, D Daldagen-Bueno, Robin J Murphy et al.

Abstract Background Depressive disorders affect about 280 million people worldwide, with many struggling to find effective relief. Conventional antidepressants are widely prescribed but often lack efficacy and have side effects, leaving many patients dissatisfied or untreated. Concurrently, psychedelic therapies have gained momentum in both research and ‘in the wild’, with emerging evidence...

597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE

The International Journal of Neuropsychopharmacology August 1, 2025 Siegfried Kasper

Abstract Background Psycholicibin is now studied in clinical settings. Aims & Objectives To elaborate if side effects are part of the therapeutic process. Method Literature overview and personal statement. Results The recent development of the socalled “psychedelics” reminds us that unfortunately some medications which we used in psychiatry have a large burden of side effects, like the...

577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES

The International Journal of Neuropsychopharmacology August 1, 2025 Hiroe Tani

Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical field have led to increasingly...